TWI627954B - 急性骨髓性白血病(aml)之新穎組合治療 - Google Patents

急性骨髓性白血病(aml)之新穎組合治療 Download PDF

Info

Publication number
TWI627954B
TWI627954B TW103142020A TW103142020A TWI627954B TW I627954 B TWI627954 B TW I627954B TW 103142020 A TW103142020 A TW 103142020A TW 103142020 A TW103142020 A TW 103142020A TW I627954 B TWI627954 B TW I627954B
Authority
TW
Taiwan
Prior art keywords
compound
day
formula
mdm2
administered
Prior art date
Application number
TW103142020A
Other languages
English (en)
Chinese (zh)
Other versions
TW201526890A (zh
Inventor
布萊恩 席金斯
Brian Higgins
關 尼可斯
Gwen NICHOLS
凱薩琳E 派克曼
Kathryn E. Packman
Original Assignee
赫孚孟拉羅股份公司
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=52014047&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TWI627954(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 赫孚孟拉羅股份公司, F. Hoffmann-La Roche Ag filed Critical 赫孚孟拉羅股份公司
Publication of TW201526890A publication Critical patent/TW201526890A/zh
Application granted granted Critical
Publication of TWI627954B publication Critical patent/TWI627954B/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/77Polymers containing oxygen of oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Saccharide Compounds (AREA)
  • Pyrrole Compounds (AREA)
TW103142020A 2013-12-05 2014-12-03 急性骨髓性白血病(aml)之新穎組合治療 TWI627954B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361912152P 2013-12-05 2013-12-05
US61/912,152 2013-12-05

Publications (2)

Publication Number Publication Date
TW201526890A TW201526890A (zh) 2015-07-16
TWI627954B true TWI627954B (zh) 2018-07-01

Family

ID=52014047

Family Applications (2)

Application Number Title Priority Date Filing Date
TW107105068A TWI678204B (zh) 2013-12-05 2014-12-03 急性骨髓性白血病(aml)之新穎組合治療
TW103142020A TWI627954B (zh) 2013-12-05 2014-12-03 急性骨髓性白血病(aml)之新穎組合治療

Family Applications Before (1)

Application Number Title Priority Date Filing Date
TW107105068A TWI678204B (zh) 2013-12-05 2014-12-03 急性骨髓性白血病(aml)之新穎組合治療

Country Status (31)

Country Link
US (5) US20160303158A1 (es)
EP (1) EP3077004B1 (es)
JP (3) JP6297695B2 (es)
KR (1) KR101862955B1 (es)
CN (1) CN105792847B (es)
AR (1) AR098576A1 (es)
AU (1) AU2014359422B2 (es)
BR (1) BR112016009669B1 (es)
CA (1) CA2926307C (es)
CL (1) CL2016001345A1 (es)
CR (1) CR20160173A (es)
DK (1) DK3077004T3 (es)
EA (1) EA201690785A1 (es)
ES (1) ES2785203T3 (es)
HK (1) HK1222808A1 (es)
HR (1) HRP20200566T1 (es)
HU (1) HUE049434T2 (es)
IL (1) IL244888B (es)
LT (1) LT3077004T (es)
MA (1) MA39040A1 (es)
MX (1) MX370618B (es)
PE (1) PE20160591A1 (es)
PH (1) PH12016500933A1 (es)
PL (1) PL3077004T3 (es)
PT (1) PT3077004T (es)
RS (1) RS60142B1 (es)
SG (1) SG11201604504VA (es)
SI (1) SI3077004T1 (es)
TW (2) TWI678204B (es)
WO (1) WO2015082384A1 (es)
ZA (1) ZA201602829B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101525754B1 (ko) 2007-03-28 2015-06-09 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 스티칭된 폴리펩티드
SI2603600T1 (sl) 2010-08-13 2019-04-30 Aileron Therapeutics, Inc. Peptidomimetični makrocikli
KR20140100937A (ko) 2011-10-18 2014-08-18 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
DK3077004T3 (da) * 2013-12-05 2020-04-27 Hoffmann La Roche Hidtil ukendt kombinationsbehandling af akut myeloid leukæmi (AML)
TW201613576A (en) 2014-06-26 2016-04-16 Novartis Ag Intermittent dosing of MDM2 inhibitor
KR20170058424A (ko) 2014-09-24 2017-05-26 에일러론 테라퓨틱스 인코포레이티드 펩티드모방 거대고리 및 이의 용도
WO2016049355A1 (en) 2014-09-24 2016-03-31 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
AU2016235424A1 (en) 2015-03-20 2017-10-05 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3344275B8 (en) * 2015-09-03 2023-04-12 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3347372A4 (en) 2015-09-10 2019-09-04 Aileron Therapeutics, Inc. PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1
US10245258B2 (en) * 2016-06-06 2019-04-02 Celgene Corporation Treatment of a hematologic malignancy with 2-(4-chlorophenyl)-N-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-5-yl)methyl)-2,2-difluoroacetamide
US10471154B2 (en) * 2016-08-08 2019-11-12 Fei Xiao Spirocyclic indolone polyethylene glycol carbonate compound, composition, preparation method and use thereof
PT3541387T (pt) 2016-11-15 2021-07-14 Novartis Ag Dose e regime para inibidores de interação de hdm2-p53
ES2942419T3 (es) * 2017-03-31 2023-06-01 Novartis Ag Dosis y pauta para un inhibidor de la interacción HDM2-p53 en tumores hemáticos
WO2020023502A1 (en) 2018-07-23 2020-01-30 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
EP3858361A4 (en) 2018-09-28 2021-12-01 FUJIFILM Corporation ANTITUMOR AGENT CONTAINING CYTARABINE, ANTITUMOR ACTIVATOR USED IN COMBINATION WITH CYTARABINE, ANTITUMOR KIT, AND ANTITUMOR AGENT USED IN COMBINATION WITH CYTARABINE
EP4003332A4 (en) * 2019-07-26 2023-05-10 Ascentage Pharma (Suzhou) Co., Ltd. PHARMACEUTICAL COMPOSITION OF MDM2 INHIBITOR AND ITS USE FOR PREVENTING AND/OR TREATING A DISEASE
EP4337228A1 (en) * 2021-05-13 2024-03-20 Nkarta, Inc. Dosing regimens for cancer immunotherapy

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101773408A (zh) * 2010-01-15 2010-07-14 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置及方法
TW201341357A (zh) * 2012-03-15 2013-10-16 Hoffmann La Roche 經取代吡咯啶-2-羧醯胺

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005530745A (ja) * 2002-05-02 2005-10-13 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害剤
DE102005012681A1 (de) * 2005-03-18 2006-09-21 Weber, Lutz, Dr. Neue 1,5-Dihydro-pyrrol-2-one
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
JP2013523820A (ja) * 2010-04-09 2013-06-17 ザ、リージェンツ、オブ、ザ、ユニバーシティ、オブ、ミシガン 疾患を処置する際に使用するためのmdm2阻害剤のバイオマーカー
JO2998B1 (ar) * 2010-06-04 2016-09-05 Amgen Inc مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان
US20120010235A1 (en) * 2010-07-12 2012-01-12 Xin-Jie Chu N-substituted pyrrolidines
US9216170B2 (en) * 2012-03-19 2015-12-22 Hoffmann-La Roche Inc. Combination therapy for proliferative disorders
DK3077004T3 (da) * 2013-12-05 2020-04-27 Hoffmann La Roche Hidtil ukendt kombinationsbehandling af akut myeloid leukæmi (AML)
US9657351B2 (en) * 2013-12-06 2017-05-23 Hoffman-La Roche Inc. MRNA-based gene expression for personalizing patient cancer therapy with an MDM2 antagonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101773408A (zh) * 2010-01-15 2010-07-14 平荧 多功能排针结合电凝固技术提升下垂皮肤的装置及方法
TW201341357A (zh) * 2012-03-15 2013-10-16 Hoffmann La Roche 經取代吡咯啶-2-羧醯胺

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
"A Study of as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia", 網址:https://clinicaltrials.gov/ct2/show/, 網頁日期:2013年1月18日. Kojima K et al,"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy", Blood, 2005 Nov 1; 106(9): 3150–3159. *
"A Study of RO5503781 as Single Agent or in Combination With Cytarabine in Patients With Acute Myelogenous Leukemia", 網址:https://clinicaltrials.gov/ct2/show/NCT01773408, 網頁日期:2013年1月18日.
Kojima K et al,"MDM2 antagonists induce p53-dependent apoptosis in AML: implications for leukemia therapy", Blood, 2005 Nov 1; 106(9): 3150–3159.

Also Published As

Publication number Publication date
DK3077004T3 (da) 2020-04-27
JP2018111700A (ja) 2018-07-19
KR20160070190A (ko) 2016-06-17
MX2016007170A (es) 2016-09-08
PT3077004T (pt) 2020-04-16
MA39040A1 (fr) 2018-01-31
HK1222808A1 (zh) 2017-07-14
KR101862955B1 (ko) 2018-05-31
MX370618B (es) 2019-12-17
CA2926307C (en) 2021-11-16
CN105792847B (zh) 2019-11-08
EP3077004A1 (en) 2016-10-12
IL244888B (en) 2020-11-30
PE20160591A1 (es) 2016-06-11
ZA201602829B (en) 2017-04-26
BR112016009669B1 (pt) 2023-01-24
RS60142B1 (sr) 2020-05-29
CN105792847A (zh) 2016-07-20
AU2014359422B2 (en) 2020-03-05
IL244888A0 (en) 2016-05-31
JP6918724B2 (ja) 2021-08-11
US20200253999A1 (en) 2020-08-13
CL2016001345A1 (es) 2017-04-07
LT3077004T (lt) 2020-05-11
JP2016539160A (ja) 2016-12-15
SI3077004T1 (sl) 2020-07-31
EP3077004B1 (en) 2020-02-19
AU2014359422A1 (en) 2016-04-28
SG11201604504VA (en) 2016-07-28
US20220031726A1 (en) 2022-02-03
CR20160173A (es) 2016-06-08
HRP20200566T1 (hr) 2020-06-26
PL3077004T3 (pl) 2020-08-10
US20160303158A1 (en) 2016-10-20
AR098576A1 (es) 2016-06-01
EA201690785A1 (ru) 2016-10-31
WO2015082384A1 (en) 2015-06-11
US20150157603A1 (en) 2015-06-11
TWI678204B (zh) 2019-12-01
US20230381215A1 (en) 2023-11-30
JP6297695B2 (ja) 2018-03-20
CA2926307A1 (en) 2015-06-11
PH12016500933A1 (en) 2016-06-27
ES2785203T3 (es) 2020-10-06
BR112016009669A8 (pt) 2020-04-07
JP2021091690A (ja) 2021-06-17
HUE049434T2 (hu) 2020-09-28
TW201526890A (zh) 2015-07-16
TW201840310A (zh) 2018-11-16
US9956243B2 (en) 2018-05-01

Similar Documents

Publication Publication Date Title
TWI627954B (zh) 急性骨髓性白血病(aml)之新穎組合治療
RU2717331C2 (ru) Применение антагонистов рецептора ep4 для лечения nash-ассоциированного рака печени
US20190262267A1 (en) Pharmaceutical solution having a toxicity-reducing effect for antitumor drugs, and pharmaceutical composition comprising same
US20240018258A1 (en) Cd47 blockade therapy with cd38 antibody
KR101628448B1 (ko) 암 치료에 사용하기 위한 베무라페닙 및 인터페론을 포함하는 병용 요법
US20190241660A1 (en) Immune-stimulating peptides and checkpoint inhibitors, and uses thereof for treating cancer
US20200230247A1 (en) Combination therapies comprising targeted therapeutics
US20190365680A1 (en) Use of ep4 receptor antagonists for the treatment of nash-associated liver cancer
Chatterji et al. Microtubules as Anti-Cancer Drug Targets
CA3100216A1 (en) Combination therapy
TW200940061A (en) Combination comprising bosentan for treating ovarian cancer